Brought to you by 
Hafslund Nycomed and Ivax to merge via stock swap
13 Jul 1999
Executive Summary
To stay market leaders in their respective niches Ivax (generics) and Hafslund Nycomed (imaging agents) will merge in a 1:1 stock swap valued at $2.5 billion that will give both companies a global scale in R&D and marketing.
Deal Industry
- Pharmaceuticals
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hafslund Nycomed and Ivax to merge via stock swap
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice